Get Retatrutide Online in Nebraska | OmniRx Health
Medical Weight Loss Treatment in Nebraska
Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).
Key Benefits
- Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
- Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
- ~58% hepatic fat reduction in Phase 2 sub-group analyses
- Elevated basal metabolic rate via glucagon receptor agonism
- Research-grade purity ≥98% with full CoA, HPLC, and MS documentation
Who is a Good Candidate?
Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.
Available for research use
Serving Nebraska
Nebraska's strength is in its people—hardworking farmers, innovative entrepreneurs in Omaha, and tight-knit communities across the plains. OmniRx Health serves this Cornhusker spirit by bringing healthcare to where you are. Whether you're in downtown Omaha, cheering for the Huskers in Lincoln, or running a cattle operation in the Sandhills, our telehealth platform connects you with expert care. No more driving hours across the state when you can consult a board-certified provider from your living room.
Our providers are licensed by the Nebraska Board of Medicine and Surgery for comprehensive statewide telehealth services.
Nebraska pharmacies in Omaha, Lincoln, and throughout rural communities ensure prescription access with reliable home delivery.
Nebraska's telehealth regulations support virtual care delivery while ensuring patient safety standards are maintained.
Nebraska insurers cover telehealth services, with ongoing efforts to expand access and ensure fair reimbursement for virtual care.
Frequently Asked Questions
- What is retatrutide and how does it work?
- Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
- How does retatrutide compare to semaglutide and tirzepatide in research?
- Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
- Is retatrutide available for human use?
- No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
- Is telehealth legal in Nebraska?
- Yes, telehealth is legal in Nebraska. The state supports virtual healthcare delivery, enabling licensed providers to offer consultations, prescriptions, and ongoing care remotely.
- Can western Nebraska residents use telehealth?
- Telehealth is essential for western Nebraska, where medical centers may be hours away. Our platform brings specialist care to Scottsbluff, North Platte, and beyond.
- Does Nebraska insurance cover telehealth?
- Most Nebraska health insurance plans cover telehealth visits. Coverage varies by plan, but virtual care is increasingly recognized as a standard healthcare delivery method.